Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Targets $48.7M in Net Proceeds from Public Offering

NEW YORK (GenomeWeb News) – Fluidigm today announced a public offering of its shares that is expected to raise $48.7 million in net proceeds.

The South San Francisco, Calif.-based firm is offering 3,660,000 shares of its common stock at $14.25 per share. The offering is expected to close on or about Aug. 21, and proceeds will go toward R&D, commercialization of its products, working capital, and other general corporate use, Fluidigm said.

Piper Jaffray and Cowen & Co. are joint book-running managers for the offering, and Leerink Swann, Oppenheimer, and Cantor Fitzgerald are co-managers. Fluidigm has granted the underwriters a 30-day option to purchase up to an additional 15 percent of the shares to cover any over-allotments.

The offering is being made pursuant to a shelf registration filed by Fluidigm in April with SEC to offer from time to time up to $100 million in securities.

As of June 30, Fluidigm had $38.9 million in cash, cash equivalents, and investments. In a document filed with the US Securities and Exchange Commission today, it said that its existing cash and cash equivalents are sufficient for at least the next 18 months.

Last week, it reported a 22 percent increase in second quarter revenues year over year. The company went public in February 2011.

In Thursday morning trading on the Nasdaq shares of Fluidigm were up around 1 percent at $14.98 on the Nasdaq.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.